CD19 and neuromyelitis optica: For example, BCMA-targeting CAR-T cells are being investigated for myasthenia gravis, while anti-CD19 and dual anti-CD19/anti-CD20 CAR-Ts are being tested for lupus and neuromyelitis optica spectrum disorders [108–110].